Pension veterans say there was more going on behind the scenes than scrutiny of costs

Sources say Harper’s name has been in the mix for at least 10 months

Humans perfected how to identify wild animals over millennia, and now biologists are rediscovering the exceptional worth of the tracks and marks left behind

Shop now to sculpt your midsection comfortably with soft, breathable fabric.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

Imagine walking into your yard with a coffee in one hand, no lawn mower in sight, and the kind of lush greenery that looks effortlessly perfect. No frantic trimming or sweating under the summer sun. Sounds too good to be true? It’s possible when you pick the right low-maintenance grass. Let’s walk through some game-changing […]

The post Looking for Low-Maintenance Grasses? Discover the Best Choices for Busy Gardeners appeared first on Chart Attack.

European Commission looks into alleged exclusivity, pricing, and patent demands.

Critics worry Anthropic is endangering its "ethical" AI stance due to defense associations.

Jyotsana Jagannathan and Brindha Manikavasagan brought alive the myriad facets of Meenakshi through their refreshing approach

Muhammad Musthafa’s sophomore directorial ‘Mura’ is a gangster drama that revolves around revenge and friendship starring a bunch of new as well as seasoned performers

Directed by Julius Onah, the upcoming film sees Ford as President Thaddeus “Thunderbolt” Ross, who offers Wilson an official role within the military, hoping to make Captain America a government ally

The inaugural Red Lorry Film Festival in 2024 saw over 100 international films across various categories and languages

Megan Fox has announced pregnancy with Machine Gun Kelly after experiencing a pregnancy loss in 2023

Getting outside – without your phone – is one way to disconnect.

The show will premiere in January 2025

Should the BBC pass the torch to a seasoned veteran or opt for a fresh voice when Lineker steps down?

The radio host criticized Jenner, a transgender woman, for supporting Donald Trump

The U.K. based aerospace company, Space Solar, plans to launch its space-based solar power plant by 2030 to deliver clean energy to Iceland, which is already a renewable-energy powerhouse.

And the Senate shouldn’t abandon its ‘advice and consent’ role.

He has a good chance of getting the case reversed on appeal — but he can’t appeal until after Judge Merchan sentences him.

Baidu, which is often called China's answer to Google, has launched its own pair of AI-powered smart glasses at its annual World Conference event in Shanghai. The device will run on the company's ERNIE generative AI technology and was designed to "become a private assistant," according to the Financial Times. Users will reportedly be able to interact with the device using their voice and ask it questions about what it sees in their current environment. They can also tell it to play music and even track their calories consumption. And since the glasses are equipped with cameras, they can ask it to snap photos or take videos. 

When the glasses start shipping sometime next year, they could become the Chinese consumers' alternative to Meta's and Snap's devices. Meta teamed up with Ray Ban a few years ago to release a pair of smart sunglasses that can livestream and send photos hands-free. Its latest model comes built-in with Meta's generative AI assistant that users can talk to. However, the company's device isn't officially sold in China, because its servers are blocked in the country. Baidu has yet to announce how much its glasses would cost, but Meta is selling its device for $299. 

The Baidu World Conference had a huge focus on the company's AI efforts, as it takes steps to make sure ERNIE can keep up with its competitors' technologies. It also launched a new AI image generator called iRAG that apparently experiences fewer hallucinations than its predecessor, along with a tool that enables people to create software programs even if they don't have coding expertise. According to The Times, ByteDance's Doubao is now the leading AI chatbot in China based on monthly active users as observed by Sensor Tower. ByteDance is also growing its hardware offerings and recently launched a pair of earbuds with access to its AI assistant Doubao. 

This article originally appeared on Engadget at https://www.engadget.com/ai/baidu-announces-its-own-pair-of-ai-smart-glasses-143044805.html?src=rss

Le grand requin blanc attaque souvent ses proies par en dessous, confondant parfois la silhouette d’un surfeur avec celle d’un phoque.

A FORMER bikini model has lodged a formal complaint with the Queensland Police Service after officers accessed her personal file more than 1400 times.

Billionaire and social media mogul Kim Kardashian finally wore the Princess Diana-owned pendant she bought last year. She debuted the amethyst and diamond cross, purchased in January 2023 for £163,800 (roughly $265,000 Cdn), at the LACMA Art+Film Gala in Los Angeles on Saturday. 

Laurence Jalbert a dû tout arrêter pendant deux mois

The Canadian Food Inspection Agency has issued a recall for several brands of bread and buns due to pieces of metal in the products.

Canadian rental prices fell 1.2 per cent in October compared to the same time last year. It's the first time that annual rents have declined since July 2021, according to a new report.

An internal report on workplace racism and harassment at the highest levels of the federal public service shows that not even the federal government’s top executives are immune from the problem.

Ottawa is finalizing its long-awaited Arctic foreign policy with Inuit leaders for release before the end of the year, as Canada braces for a second Trump presidency and increasing threats to its sovereignty from China and Russia.

The national chief of the Assembly of First Nations says the International Criminal Court should investigate the disappearance of Indigenous children from Canadian residential schools.

Indian and multinational pharma companies are leading the charge by investing in digital transformation and aligning Indian operations with global standards. Essentially, pharmaceutical water systems are

The Federation of Pharmaceutical Entrepreneurs (FOPE) has identified potential opportunities for Indian pharmaceutical companies to expand in Australia. Further, the India─Australia Economic Cooperation and Trade

The Indian Council of Medical Research (ICMR) has issued a call for proposals for its Centre for Advanced Research (CAR) initiative under the Extramural Research Programme, inviting experienced research teams to

The centrally sponsored scheme for strengthening of medical devices industry (SMDI), launched by the Central government last week, was widely welcomed by the medical devices industry in the country.

The National Accreditation Board for Testing and Calibration Laboratories (NABL), under the Quality Council of India (QCI), has announced a collaborative effort with Man─Made Textile Research Association (MANTRA) in Surat to deliver a specialized technical training programme on medical textiles testing.

Placon, an innovator in the medical packaging market, announced the release of a new stock line of BargerGard TPU pouches and tip protectors.

Ampacet has introduced ProVital+ Gamma-Protect, a medical-grade additive designed to preserve mechanical and optical properties of polypropylene-based medical and pharmaceutical articles during gamma and e-beam sterilisation processes.

Dr Euan McBrearty, head of commerical & innovation, Wideblue shares five steps to successful medical device development.

The outcome of the 2024 U.S. presidential election could reshape policies from health care at home to nuclear proliferation abroad

The outcome of the 2024 U.S. presidential election could set the climate agenda, reshape public education and shift the dynamics of global science collaboration.

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health

Josh discusses challenges manufacturers may face when outsourcing patient support programs. He outlines a process that smoothly transitions hubs and minimizes disruptions for patients and healthcare providers.

To learn more, download the 3-step guide to patient hub transitions.

Read on for Josh’s insights.
Read more »

Today’s guest post comes from George Moore, Chief Information Technology Officer at CareMetx.

As George explains using novel survey data, manufacturers view new technologies  as crucial for patient services. He then explains how digital technology, artificial intelligence (AI), and machine learning (ML) can be used to improve patient adherence and increase hub efficiencies.

To learn more, download CareMetx’s new 2024 Patient Services Report: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage.

Read on for George’s insights.
Read more »

Informa Connect's Copay, Reimbursement and Access Congress
November 18-20, 2024 | Hilton Penn’s Landing in Philadelphia, PA
Drug Channels readers save 10% with code USAVE24*

The access and affordability landscape is undergoing a seismic shift. Evolving legislation, disruptive market forces and the ever-growing complexities of cost sharing programs threaten patient adherence and commercialization strategies. Are you ready?

A program driven by marketplace insights and led by industry trailblazers, Copay, Reimbursement and Access Congress is back November 18-20 and will deliver up-to-date insights necessary to enhance patient affordability, ensure program sustainability and navigate the regulatory landscape. In a time where remaining compliant has never been more complex and program innovation has never been more important, be sure to join your industry counterparts to drive adherence, access and commercialization forward.

Why attend the Copay, Reimbursement and Access Congress?

Keeping up with shifting market dynamics in the midst of maximizing access, while also meeting business objectives is a challenging task and brings about many questions for access professionals.

• Is your program sustainable and innovative to better support patients?
• Accumulators, maximizers, AFPs – What are your next steps to ensure effective reimbursement strategies?
• In an election year, what is the future of health policy?

Experts will tackle these questions and more as the industry comes together to benchmark best practices to accelerate access and commercialization. Do not miss your chance to join seasoned leaders, your peers and leading solution providers as they navigate marketplace trends and dive into the impact coupons, benefit design, accumulators, maximizers, alternative funding programs and drug pricing legislation have on patient affordability and out-of-pocket costs. This is your chance to gain critical insights on industry standards, forward-thinking strategies to optimize your copay and cost sharing programs and so much more.

Content highlights:

• Over 20 hours of content, including 7+ dedicated sessions to help decipher copay legislation
• Crucial perspectives from Pfizer, Sanofi, Janssen, Teva, Ascendis Pharma, Melinta Therapeutics, GSK, HIV + Hepatitis Policy Institute and more
• Insights direct from enforcement agents on the top trends and actions within the copay and patient services space
• Illuminating case study, Navigating the Patient Journey in a Shifting Copay Landscape from Spark Therapeutics
• 465 minutes of valuable in-person networking with colleagues and counterparts to expand your network and establish powerful partnerships
• Additional content access through Streamly, a platform that gives you 12-month access to all of the available conference content** to review at your leisure
• And more!

Download the agenda and register today—Be sure to use your exclusive promo USAVE24 to save 10% off* of your registration

See you there!

*Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.
**Pending speaker permissions

---

The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs). The FTC rightly calls out how the gross-to-net bubble can raise patients’ out-of-pocket costs, while also acknowledging how rebates can reduce a plan's (but not the patient’s) costs. Apparently, the FTC believes that PBMs’ customers are pretty dumb, because PBMs are able to prevent plans from “appreciating” such healthcare financing dynamics.

Section V.E. of the complaint (starting on page 23) focuses on the PBMs’ alleged unlawful conduct related to preferring high-list/high-rebate insulin products over versions with lower list prices. I thought it would therefore be fun to take the Wayback Machine to November 2021, when I wrote about this specific topic.

Below, you can review my commentary about the warped incentives behind Viatris’ dual-pricing strategy for its interchangeable biosimilar of Lantus. Much of the FTC’s description of the drug channel aligns with my commentary. But before you fist pump too hard for Ms. Khan’s FTC, you should pause to reflect on the agency’s legal theories in light of plans’ revealed preferences.

---

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release.

Alas, I’m sad to report that the warped incentives baked into the U.S. drug channel will limit the impact of this impressive breakthrough.

Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar. However, only the high-list/high-rebate, branded version will be available on Express Scripts’ largest commercial formulary. Express Scripts will block both the branded reference product and the lower-priced, unbranded—but also interchangeable—version. Meanwhile, Prime Therapeutics will place both versions on its formularies, leaving the choice up to its plan sponsor clients.

Consequently, many commercial payers will adopt the more expensive product instead of the identical—but cheaper—version. As usual, patients will be the ultimate victims of our current drug pricing system.

Below, I explain the weird economics behind this decision, highlight the negative impact on patients, and speculate on what this all could mean for biosimilars’ future. Until plan sponsors break their addiction to rebates, today’s U.S. drug channel problems will remain.
Read more »

Today’s guest post comes from Timothy Nielsen, Vice President of Customer Success at AssistRx.

Timothy discusses the affordability and patient journey challenges of specialty-lite products for patients, manufacturers, and health care providers. He explains how AssistRx's Advanced Access Anywhere (AAA) solution streamlines processes for specialty-lite products and facilitates enrollment via a digital hub.

To learn more, register for AssistRx's free webinar on October 8: Meet Your Patients Where They Are & Gain Visibility: Even at Retail.

Read on for Timothy’s insights.
Read more »

Today’s guest post comes from Greg Skalicky, President, EVERSANA and Faruk Abdullah, President, Professional Services & Chief Business Officer, EVERSANA

Greg and Faruk walk through the marketplace pressures driving Direct-to-Patient commercialization models. They argue that a technology-enabled infrastructure,  combined with clinical and reimbursement support specialists, can improve  patients' access to new therapies, shorten the time to therapy, and enable better overall clinical outcomes.

Click here to learn more about EVERSANA’s Direct-to-Patient care model.

Read on for Greg and Faruk’s insights.
Read more »

Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx.

Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily.

To learn more, download CareMetx’s new 2024 Patient Services Report: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage.

Read on for Shabbir’s insights.
Read more »

Today’s guest post comes from Kimberley Chiang, Vice President of Biopharma Commercial Solutions at CoverMyMeds

Kimberley highlghts the crucial roles of field reimbursement managers in removing access and reimbursement barriers. She then identifies the keys to successful implementation of field reimbursement services.

To learn more, register for CoverMyMeds' November 13, 2024, webinar: Specialty Therapies & Field Reimbursement Services: Driving Better Outcomes for Brands and Patients.

Read on for Kimberley’s insights.
Read more »